Plowshare Therapies is drawing national attention for its approach to developing treatments for rare diseases. Two leading biotechnology news outlets, STAT and Endpoints News, recently published features examining the science, community involvement, and determination behind Plowshare's mission.
STAT | October 27, 2026
Pennsylvania Dutch country, tired of waiting for biopharma, builds drug company of its own
STAT examines how Plowshare Therapies emerged from the determination of families, researchers, and clinicians working to address rare diseases that have historically received limited attention from the pharmaceutical industry. The story explores Plowshare's community-driven approach to advancing promising treatments, including its innovative work involving gene therapy.
Read the Full Story at STATA STAT+ subscription may be required.
Endpoints News | October 27, 2026
Backed by Amish and Mennonites, a new kind of gene therapy company takes shape
Endpoints News takes a closer look at Plowshare's distinctive model for rare-disease therapy development. The feature highlights the role of Amish and Mennonite communities in supporting research and the company's efforts to bring scientific advances closer to the families who need them.
Read the Full Story at Endpoints NewsPublisher registration or subscription may be required.
These stories offer a closer look at the people, partnerships, and scientific ambitions driving Plowshare Therapies' work to advance treatments for rare diseases.